1. Xiu, Mengxi, Bao, Wenfang, Wang, Jialin, Li, Yandong, Hai, Yanan. 2023. High USP32 expression contributes to cancer progression and is correlated with immune infiltrates in hepatocellular carcinoma. In BMC cancer, 23, 1105. doi:10.1186/s12885-023-11617-4. https://pubmed.ncbi.nlm.nih.gov/37957631/
2. Chandrasekaran, Arun Pandian, Kaushal, Kamini, Park, Chang-Hwan, Kim, Kye-Seong, Ramakrishna, Suresh. 2021. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2. In Theranostics, 11, 9752-9771. doi:10.7150/thno.63806. https://pubmed.ncbi.nlm.nih.gov/34815782/
3. Chen, Sifang, Chen, Xi, Li, Zhangyu, Tan, Guowei, Wang, Zhanxiang. 2022. Identification of ubiquitin-specific protease 32 as an oncogene in glioblastoma and the underlying mechanisms. In Scientific reports, 12, 6445. doi:10.1038/s41598-022-09497-y. https://pubmed.ncbi.nlm.nih.gov/35440702/
4. Nakae, Aya, Kodama, Michiko, Okamoto, Toru, Jenkins, Nancy A, Kimura, Tadashi. 2021. Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. In Biochemical and biophysical research communications, 552, 120-127. doi:10.1016/j.bbrc.2021.03.049. https://pubmed.ncbi.nlm.nih.gov/33744759/
智鼠故事 
